• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Study: Fish Oil Doesn ’ t Seem To Prevent Heart Problems
This study is consistent with earlier trials. The US Food and Drug Administration approved the fish oil-based drug Vascepa for heart attack and stroke prevention in 2019. Nissen hopes the FDA will take a look at these studies and reconsider that decision. “But it’s hard to get something undone once the genie gets out of the bottle,” he said. An editorial in the journal that accompanies the study written by Dr. Gregory Curfman, assistant professor of medicine at Harvard Medical School, also suggested the FDA should require a postmarketing clinical trial of a high-dose of fish oil, such as Vascepa, vs. corn...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 16, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Health Syndicated CBSN Boston CNN fish oil Source Type: news

Icosapent Ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Authors: Bazarbashi N, Miller M Abstract INTRODUCTION: Icosapent Ethyl (IPE) is a highly purified (>96%) form of eicosapentanoic acid, a marine-derived omega-3 fatty acid known to reduce serum triglyceride levels. Experimental and human studies also support anti-atherosclerotic properties of IPE including antioxidant, anti-inflammatory, endothelial and plaque stabilizing effects. In the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)l),the addition of 4 grams IPE daily resulted in a 25% reduction in cardiovascular events beyond statins and other standard of care therapies. ...
Source: Expert Review of Cardiovascular Therapy - April 2, 2020 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research